Treatment with anti-myeloma chemotherapy, radiotherapy, biological, immunotherapy or an investigational therapy, including targeted small molecule agents within  weeks or  half-lives (whichever is longer and/or applicable) before first dose.
Subject has received small molecule therapy, radiotherapy, immunotherapy, monoclonal antibodies, investigational drug, or chemotherapy within  days before first dose of study drug, with the exception of hydroxyurea
Have received treatment with an investigational small molecule less than  weeks before the first dose of AG-. In addition, the first dose of AG- should not occur before a period greater than or equal to  half-lives of the investigational small molecule has elapsed.
Prior treatment with small molecule bromodomain and extra terminal (BET) family inhibitor.
Chemotherapy, monoclonal antibody, or small molecule kinase inhibitor =<  days prior to first administration of study treatment
Non-cytotoxic small molecule therapeutics: ? T/ or ? weeks (whichever is longer)
Subject has received anticancer therapies including chemotherapy, radiotherapy or other investigational therapy, including targeted small molecule agents within  half-lives prior to first dose of study drug
Received investigational therapy (e.g. small molecule or biologic) within  days prior to the start of CMP- dosing on WD. However, if an investigational therapy has a short half-life, a reduced wash out period may be acceptable with Sponsor approval. Acceptable washout periods include:
Chemotherapy, small molecule inhibitors, radiation, and/or other investigational anticancer agents (excluding investigational monoclonal antibodies):  weeks.
Treatment with any small molecule investigational medicinal product (IMP) within  days prior to first dose
Prior treatment with any LAG- targeting biologic or small molecule
Receipt of a small molecule anticancer agent, including an investigational anticancer small molecule, within  days of starting study treatment
Prior chemotherapy, small molecule inhibitors, and/or other investigational anticancer agents (excluding investigational monoclonal antibodies) within  weeks
Concurrent cancer treatment with cytoreductive therapy, radiotherapy, cytokine therapy, cytotoxic agents, targeted small molecule therapy or any investigational anticancer small molecule drugs within  weeks prior to the start of study treatment (except  weeks from last dose of nitrosourea compound) OR treatment with monoclonal antibodies within  weeks prior to the start of study treatment, with the following exceptions:
Treatment with chemotherapy, immunotherapy, radiotherapy, targeted small molecule\r\ninhibitors, biologic agents, and/or an investigational therapy for  half-lives prior to first study dose of venetoclax; treatment with a biologic agent, such as a monoclonal antibody, for  days prior to study treatment; treatment with ibrutinib is allowed
Subject has received small molecule therapy, radiotherapy, immunotherapy, monoclonal antibodies, investigational drug, or chemotherapy within  days before first dose of study drug, with the exception of hydroxyurea
Treatment with an investigational small molecule less than  weeks before the first dose of CPI-
Chemotherapy, small molecule inhibitors, radiation, and/or other investigational anticancer agents (excluding investigational monoclonal antibodies):  weeks
Receipt of a small molecule anticancer agent, including an investigational anticancer small molecule, within  days of starting study treatment
Chemotherapy: non-cytotoxic (e.g., small molecule inhibitor) At least  days
Non-cytotoxic chemotherapy (e.g., small molecule inhibitor); at least  days since last dose
Treatment with an investigational small molecule less than  weeks before the first dose of CPI-. In addition, the first dose of CPI- should not occur before a period equal to or greater than  half-lives of the small molecule investigational agent has elapsed.
Receipt of a small molecule anticancer agent, including an investigational anticancer small molecule, within  days of starting study treatment or receipt of a biologic anticancer agent (e.g., antibody) within  days of starting study treatment.
Small molecule therapy, radiotherapy, immunotherapy, monoclonal antibodies, or chemotherapy within  weeks before first dose of study drug
Small-molecule inhibitors: interval >=  week from last dose before study enrollment; if a previously used agent has a prolonged half-life, the appropriate interval will be determined after consultation with the principal investigator
?  x PK half-life of a small molecule therapeutic not otherwise defined above
Less than or equal to  weeks since receiving treatment with biologic, small molecule, chemotherapy or other agent for non-small cell lung cancer and  days since any prior immunotherapy (such as nivolumab)
Currently or previously treated with biologic, small molecule, immunotherapy, chemotherapy, or other agents for metastatic pancreatic carcinoma
Prior treatment with small molecule inhibitors of the MET pathway.
Treatment with an investigational small molecule less than  weeks before the first dose of CPI-. In addition, the first dose of CPI- should not occur before a period equal to or greater than  half-lives of the small molecule investigational agent has elapsed
Prior treatment with small molecule bromodomain and extra terminal family inhibitor
Cytotoxic therapies or targeted agents that are small molecule inhibitors for  half-lives or at least  days.
Patients may not have received cytotoxic, biologic or small molecule kinase inhibitor systemic therapy for at least  weeks prior to the first dose of study treatment
Systemic anti-cancer treatment with a small molecule therapeutic (other than Ruxolitinib for the Combination arm) other than hydroxyurea less than  weeks before the first dose of CPI-
Treatment with an investigational small molecule less than  weeks before the first dose of CPI-. In addition, the first dose of CPI- should not occur before a period equal to or greater than  half-lives of the small molecule investigational agent has elapsed
Patient must not have undergone therapy with any VEGF monoclonal antibodies in the last twelve weeks; patient must not be receiving any small molecule anti-VEGF drug within previous  weeks
Cytotoxic chemotherapy, radiotherapy, or immunotherapy within  weeks, or small molecule or investigational agents within  elimination half-lives of the first dose of XmAb
Systemic antineoplastic therapy (including cytotoxic chemotherapy and toxin immunoconjugates, but excluding hydroxyurea), unconjugated antibody therapy, or radiotherapy within  weeks of the first dose of study treatment, or small molecule kinase inhibitors within  elimination half-lives of the first dose of study treatment.
